Latest Kyowa Kirin News & Updates

See the latest news and media coverage for Kyowa Kirin. We track all announcements, press releases, and industry mentions in real time, all in one place.

Company icon
Kyowa Kirin

Global specialty pharmaceutical company

kyowakirin.com
Headquarters
Chiyoda-ku, Japan
Company type
Public company
Number of employees
5,000–10,000

Last updated

Latest news about Kyowa Kirin

In short: Kyowa Kirin reported strong financial growth and secured FDA approval for its AML treatment ziftomenib while discontinuing trials for rocatinlimab.

Company announcements

Kyowa Kirin

Kyowa Kirin plans state-of-the-art research hub

The hub integrates Fuji and Tokyo sites at Yokohama to enhance drug discovery, translational research, and CMC collaboration as part of Vision 2030. Fuji and Tokyo sites may close.

Kyowa Kirin

Kyowa Kirin releases FY2026 Q1 financial results

Revenue reaches 118.5 billion yen, up 13% year-over-year. Core profit grows 78%. Forecasts updated.

Unlock all announcements with a

Media coverage

株式新聞

Kyowa Kirin rises for 4 consecutive days, SMBC Nikko Securities raises target price

Kyowa Kirin <4151.T>, which handles medical drugs for kidney, cancer, immunology/allergy, central nervous system, etc., has been rising for four consecutive days. At the high, it reached 2,553.5 yen, up 92 yen from the previous day. The target price hike by SMBC Nikko Securities was well received. On the 28th, SMBC Nikko Securities maintained its investment rating 'buy' (second of three levels) for Kyowa Kirin while raising its target price from 2,200 yen to 2,600 yen. Regarding Faserna (for severe asthma, etc.), which will arrive after May 2028...

The Wall Street Journal

Kyowa Hakko Kirin Co. Ltd. ADR

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the...

Nikkei

Kyowa Kirin faces restructuring speculation as pressure mounts to dissolve parent-subsidiary listing

Kyowa Kirin failed to develop a promising new drug, and speculation about restructuring has begun to strengthen in the stock market. Doubts are spreading about the growth of the company as a listed subsidiary of Kirin Holdings (HD). A maximum investment of 700 billion yen, being considered as a recovery measure, holds the key to its fate. Kyowa Kirin's stock price made an inexplicable move in April. In early March, the company announced the complete discontinuation of clinical trials for the atopic dermatitis treatment candidate 'Rocatinlimab,' causing a sharp drop in its stock price. After that, it...

Unlock all articles with a

Never miss news about Kyowa Kirin

Track Kyowa Kirin and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.

Trending companies

Discover what's making headlines across other trending companies.